Payment overview · 2025
General Payments
$861.87
53 reported records · 17 companies
Healthcare provider profile · identity verified
Sandra Kay Marshall
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · NORTH WILKESBORO, NC · NPI 1992438998
Verified facts
What the public records show
CMS Open Payments records show Sandra Kay Marshall received $861.87 in general payments during 2025 across 53 reported records.
ABBVIE INC. accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 334 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BELBUCA as an associated drug or biological on 17475 records involving 4385 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Belbuca by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $227.20 | 26.4% | 22 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $184.71 | 21.4% | 9 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $93.61 | 10.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.06 | 5.9% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $50.99 | 5.9% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.36 | 3.5% | 1 | 2025 |
| Forte Bio-Pharma LLC | Unresolved — no canonical attribution shown | $26.74 | 3.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.82 | 2.9% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $24.78 | 2.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.31 | 2.7% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $21.30 | 2.5% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $18.59 | 2.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.50 | 2.1% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.88 | 2.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.68 | 2.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.35 | 1.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.99 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $861.87 | 53 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $149.28 | 15 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $103.02 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $93.61 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $62.47 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $62.47 | 6 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $50.99 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $47.38 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $30.36 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.82 | 2 | 2025 |
Source payment records
|
|||||
| NALOCET Normalized: nalocet |
Drug | Forte Bio-Pharma LLC | $26.74 | 1 | 2025 |
Source payment records
|
|||||
| PROLATE Normalized: prolate |
Drug | Forte Bio-Pharma LLC | $26.74 | 1 | 2025 |
Source payment records
|
|||||
| TANLOR Normalized: tanlor |
Drug | Forte Bio-Pharma LLC | $26.74 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.31 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Carnation Ambulatory Monitor Normalized: hillrom carnation ambulatory monitor |
Device | Baxter Healthcare | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| XTAMPZA Normalized: xtampza |
Drug | Collegium Pharmaceutical, Inc. | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 144 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
334 | 97 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | 11 |
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | BELBUCA open payments reported associated product |
CMS Open Payments — General Payments 17475 supporting records · 4385 recipient NPIs · example record 1224105020 |
Belbuca · 2024 Exact normalized brand match · 1 Part D row |
32 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
144 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
162 | 48 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
89 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 853 | 241 |
| Oxycodone Hcl | Oxycodone Hcl | 787 | 226 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 484 | 129 |
| Farxiga | Dapagliflozin Propanediol | 334 | 97 |
| Gabapentin | Gabapentin | 232 | 73 |
| Pregabalin | Pregabalin | 222 | 70 |
| Naloxone Hcl | Naloxone Hcl | 209 | 199 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 173 | 79 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 173 | 60 |
| Atorvastatin Calcium | Atorvastatin Calcium | 166 | 81 |
| Ozempic | Semaglutide | 162 | 48 |
| Allopurinol | Allopurinol | 144 | 50 |
| Mounjaro | Tirzepatide | 144 | 33 |
| Glipizide | Glipizide | 137 | 47 |
| Tizanidine Hcl | Tizanidine Hcl | 124 | 52 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 113 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 39 |
| Omeprazole | Omeprazole | 100 | 52 |
| Trazodone Hcl | Trazodone Hcl | 98 | 35 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 96 | 33 |
| Levothyroxine Sodium | Levothyroxine Sodium | 90 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 89 | 46 |
| Rybelsus | Semaglutide | 89 | 22 |
| Xtampza Er | Oxycodone Myristate | 78 | 26 |
| Celecoxib | Celecoxib | 76 | 27 |
| Meloxicam | Meloxicam | 76 | 60 |
| Montelukast Sodium | Montelukast Sodium | 76 | 37 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 74 | 33 |
| Topiramate | Topiramate | 74 | 23 |
| Tramadol Hcl | Tramadol Hcl | 74 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 40 |
| Morphine Sulfate Er | Morphine Sulfate | 67 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 67 | 27 |
| Lisinopril | Lisinopril | 65 | 35 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 29 |
| Potassium Chloride | Potassium Chloride | 59 | 22 |
| Buspirone Hcl | Buspirone Hcl | 56 | 23 |
| Alprazolam | Alprazolam | 55 | 13 |
| Prednisone | Prednisone | 50 | 30 |
| Losartan Potassium | Losartan Potassium | 49 | 28 |
| Alendronate Sodium | Alendronate Sodium | 47 | 20 |
| Clonazepam | Clonazepam | 46 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | 27 |
| Furosemide | Furosemide | 44 | 22 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 42 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 40 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 26 |
| Azithromycin | Azithromycin | 39 | 37 |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | 14 |
| Febuxostat | Febuxostat | 39 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 38 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 14 |
| Sertraline Hcl | Sertraline Hcl | 37 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 16 |
| Morphine Sulfate | Morphine Sulfate | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | 13 |
| Cephalexin | Cephalexin | 34 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 34 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 17 |
| Baclofen | Baclofen | 32 | 13 |
| Belbuca | Buprenorphine Hcl | 32 | 17 |
| Linzess | Linaclotide | 31 | 17 |
| Metformin Hcl | Metformin Hcl | 30 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 30 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 29 | 13 |
| Eliquis | Apixaban | 29 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | 11 |
| Dapagliflozin | Dapagliflozin Propanediol | 26 | 22 |
| Famotidine | Famotidine | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | 11 |
| Atenolol | Atenolol | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | 11 |
| Simvastatin | Simvastatin | 22 | 15 |
| Amoxicillin | Amoxicillin | 21 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 17 |
| Carvedilol | Carvedilol | 19 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 18 | suppressed |
| Oxycontin | Oxycodone Hcl | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | 11 |
| Fluconazole | Fluconazole | 17 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 16 |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 16 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Trulance | Plecanatide | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Butalbital-Acetaminophen | Butalbital/Acetaminophen | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $861.87 · 53 records | ABBVIE INC. | ACCRUFER, AIRSUPRA, BREZTRI, CAPLYTA, Dexcom G6 Transmitter, Hillrom - Carnation Ambulatory Monitor, Kerendia, MAVYRET, MOUNJARO, NALOCET, PROLATE, QULIPTA, REXULTI, SUBLOCADE, Symbravo, TANLOR, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Wegovy, XTAMPZA, YUPELRI, ZEPBOUND, ZTLido | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error